Streamlining production footprint and improving manufacturing efficiency through phased closure of Holliston, MA plant Initiative expected to ...

Holliston biotechnology firm Harvard Bioscience continued its fourth quarter momentum with revenue up 14% in the first quarter of 2021 when compared to the first quarter of 2020. Holliston ...

HOLLISTON, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (HBIO) will announce its financial results for the quarter ended June 30, 2025, before the market opens on August 11, 2025, ...

Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial Flexibility BroadOak Partner Bill Snider to Join Board of Directors and Company to Form Advisory Board ...

The MarketWatch News Department was not involved in the creation of this content. HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or ...

Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board members Q2 ’25 revenue anticipated to be $20.4 million and Company reiterates ...

Operator: Good day, and welcome to the Third Quarter 2025 Harvard Bioscience Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the ...

Jim Green will retire from his roles as chairman, president, and CEO of Harvard Bioscience on July 28. Harvard Bioscience falls out of Nasdaq compliance after board member resignation Harvard ...

Harvard Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.025. Operator: Good day, and welcome to the Second Quarter 2025 Harvard Bioscience Earnings ...